Euroasian Journal of Hepato-Gastroenterology

Register      Login

VOLUME 2 , ISSUE 2 ( July-December, 2012 ) > List of Articles

ORIGINAL ARTICLE

Metabolic Syndrome in Inflammatory Bowel Disease: A Real Relationship or Just a Coincidence

Mesut Sezikli, Züleyha Akkan Cetinkaya, Fatih Güzelbulut, Demet Özgil Yetkin

Citation Information : Sezikli M, Akkan Cetinkaya Z, Güzelbulut F, Özgil Yetkin D. Metabolic Syndrome in Inflammatory Bowel Disease: A Real Relationship or Just a Coincidence. Euroasian J Hepatogastroenterol 2012; 2 (2):79-83.

DOI: 10.5005/jp-journals-10018-1039

License: CC BY-NC 4.0

Published Online: 01-07-2012


Abstract

Background and aim: Presence of metabolic syndrome along with inflammatory diseases is being reported with increased frequency. The aim of this study was to investigate the presence of metabolic syndrome in inflammatory bowel disease patients. Materials and methods: Fifty-one patients with ulcerative colitis, 34 patients with Crohn’s disease and 88 healthy controls were included in this study. All of the patients were in remission state. Subjects were classified as having the metabolic syndrome based on the National Cholesterol Education Program (NCEP) and the modified World Health Organization (WHO) definition. Results: The prevalence of metabolic syndrome in patients with ulcerative colitis was 16% according to the NCEP and 23.5% according to the WHO, and that in patients with Crohn’s disease was 8.8% according to the NCEP and 14.7% according to the WHO. The prevalence of metabolic syndrome in control group was 18% according to the NCEP and 15.7% according to the WHO. When inflammatory bowel disease patients and control groups were compared with respect to the presence of metabolic syndrome, there was no statistically significant difference between the two groups according to neither NCEP nor WHO. Conclusion: Although it is predicted that metabolic syndrome develops lesser since inflammatory bowel disease patients as they are considered to have lower body mass index, frequency of metabolic syndrome is not less than control group according to the results of our study. Therefore, possibility of metabolic syndrome in inflammatory bowel disease patients should not be overlooked and it should be considered that it can be used in patient follow-up.


PDF Share
  1. Cobrin GM, Abreu MT. Defects of mucosal immunity leading to Crohn’s disease. Immunol Rev 2005;206:277-95
  2. Defects of mucosal immunity leading to ulcerative colitis. Immunol Rev 2005;206:296-305
  3. Relation between plasma tumor necrosis factor-alpha and insulin sensitivity in elderly men with non-insulin-dependent diabetes mellitus. Arterioscler Thromb Vasc Biol 1998;18:1199-202
  4. Prevalence of the metabolic syndrome is increased in rheumatoid arthritis and is associated with coronary atherosclerosis. Atherosclerosis 2008;196:756-63
  5. High prevalence of the metabolic syndrome in patients with systemic lupus erythematosus: Association with disease characteristic and cardiovascular risk factors. Ann Rheum Dis 2007;66:208-14
  6. The incidence of arterial thromboembolic diseases in inflammatory bowel disease: A population based study. Clin Gastroenterol Hepatol 2008;6:41-45
  7. Metabolic syndrome and gastrointestinal diseases. J Gastroenterol 2007;42:267-74
  8. Homeostasis model assessment: Insulin resistance and beta cell function from fasting plasma glucose and insulin consentrations in man. Diabetologia 1985;28:412-19
  9. Evaluation and treatment high blood cholesterol in adults (adult treatment panel III). JAMA 2001;285:2486-97
  10. Measures of insulin resistance and incremental value to the clinical diagnosis of metabolic syndrome in association with coronary atherosclerosis. Circulation 2004;110:1070-77
  11. Physical activity, obesity and risk for colon cancer and adenoma in men. Ann Intern Med 1995;122:327-34
  12. Ulcerative colitis and Crohn’s disease: A comparison of the colorectal cancer risk in extensive colitis. Gut 1994;35:1590-92. Metabolic Syndrome in Inflammatory Bowel Disease: A Real Relationship or Just a Coincidence Euroasian Journal of Hepato-Gastroenterology, July-December 2012;2(2):79-83 83 EJOHG 13. Hass DJ, Brensinger CM, Lewis JD, Lichtenstein GR. The impact of increased body mass index on the clinical course of Crohn’s disease. Clin Gastroenterol Hepatol 2006;4:482-88
  13. Mesenteric fat in Crohn’s disease: A pathogenetic hallmark or an innocent bystander? Gut 2007;56:577-83
  14. Cardiovascular morbidity and mortality associated with the metabolic syndrome diabetes Care 2001;24:683-89
  15. Geneva, World Health Organisation, 1999
  16. Comment on the provisional report from the WHO consultation. European group for the study of insulin resistance (EGIR). Diabet Med 1999,16:442-43
  17. JAMA 2001;285:2486-97
  18. American college of endocrinology position statement on the insulin resistance syndrome. Endocr Pract 2003;9:237-52
  19. The metabolic syndrome: A new worldwide definition. Lancet 2005;366:1059-1062
  20. Analysis of agreement among definitions of metabolic syndrome in nondiabetic Turkish adults: A methodological study. BMC Public Health 2007;7:353
  21. The national cholesterol education program: Adult treatment panel III, international diabetes federation, and World Health Organization definitions of the metabolic syndrome as predictors of incident cardiovascular disease and diabetes. Diabetes Care 2007; 30:8-13
  22. Comparison of different definitions of the metabolic syndrome. Eur J Clin Invest 2007;37:109-16
  23. Prevalance of metabolic sydrome is comparable between inflammatory bowel disease patients and the general population. J Gastroenterol 2010;45: 1008-13
  24. Is inflammatory bowel disease a risk factor for early atherosclerois? Angiology 2010; 61:198-204
  25. Body composition, insulin, and leptin levels in patients with ankylosing spondylitis. Clin Rheumatol 2007;26:1427-32
  26. Immunreactive insulin levels in ankylosing spondylitis. Arch Invest Med 1991;22: 121-25
  27. Antitumor necrosis factor-alpha blockade improves insulin resistance in patients with rheumatoid arthritis. Clin Exp Rheumatol 2006; 24:83-86
  28. Effects of infliximab treatment on insulin resistance in patients with rheumatoid arthritis and ankylosing spondylitis. Ann Rheum Dis 2005;64:765-66
  29. Current directions of biologic therapies in inflammatory bowel disease. Therap Adv Gastroenterol 2010;3:99-106.
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.